• News & Media
  • Contact
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Grants & Funding
    • Investigator Sponsored Studies
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • KOMET-007 – AML
    • KOMET-008 – AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN – HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 – Solid Tumors
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • News & Media
  • Contact
  • Menu Menu

Asking the Right Questions in R&D

May 2, 2025/in 2025, Media Coverage, Perspectives
Read more
https://kuraoncology.com/wp-content/uploads/MedicineMaker.jpg 366 670 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2025-05-02 11:00:192025-06-17 13:26:40Asking the Right Questions in R&D

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

May 2, 2025/in 2025, Media Coverage, Perspectives
Read more
https://kuraoncology.com/wp-content/uploads/PharmaVoice.jpg 366 670 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2025-05-02 10:00:322025-06-17 13:26:44PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

Scrip Asks… What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

May 2, 2025/in 2025, Media Coverage, Perspectives
Read more
https://kuraoncology.com/wp-content/uploads/ScripAsks5.jpg 366 670 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2025-05-02 09:00:172025-06-17 13:26:47Scrip Asks… What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni, Kura Oncology

August 1, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/Empowered_Patient_Podcast.jpg 450 800 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-08-01 15:00:432024-08-01 16:43:02Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni, Kura Oncology

Menin inhibitors seek to debut as newest targeted therapy for leukaemia

August 1, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/Nature.jpg 450 800 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-08-01 13:00:102024-11-06 12:49:06Menin inhibitors seek to debut as newest targeted therapy for leukaemia

Moving Forward, Giving Back: The ROI of Social Impact

June 27, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/MovingForwad_GivngBack.jpg 450 800 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-06-27 13:00:032024-06-28 10:28:21Moving Forward, Giving Back: The ROI of Social Impact

Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

March 21, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/OncLive.png 304 557 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-03-21 18:38:282024-03-21 19:49:24Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

Kura Oncology Reports Preliminary Data From Menin Inhibitor, Chemo Combination Trial in AML

March 21, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/Precision_Medicine_Online.png 304 557 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-03-21 18:20:582024-11-06 12:12:16Kura Oncology Reports Preliminary Data From Menin Inhibitor, Chemo Combination Trial in AML

Kura’s Leukemia Treatment Performs Best When Tacked Onto Existing Combo, New Data Show

March 21, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/fierce_bio.png 304 557 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-03-21 11:43:012024-03-22 15:20:19Kura’s Leukemia Treatment Performs Best When Tacked Onto Existing Combo, New Data Show

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

February 15, 2024/in 2024, Media Coverage, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/SC2402_Scrip-Asks-24-Part-5_1888758571_1200.jpg 444 790 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-02-15 13:38:472024-02-15 13:39:44Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Page 1 of 3123
  • About Us
  • Our Commitment
  • The Story Behind Our Name
  • Leadership
  • Board of Directors
  • Grants & Funding
  • Investigator Sponsored Studies
  • Our Approach
  • Precision Medicines
  • Overcoming Resistance
  • Novel Biomarkers
  • Pipeline
  • Ziftomenib
  • Tipifarnib
  • KO-2806
  • Posters and Presentations
  • Scientific Manuscripts
  • Access to Investigational Drugs Outside a Clinical Study
  • Clinical Trials
  • Overview of Clinical Trials
  • Ziftomenib Clinical Trials
  • KOMET-001 – AML
  • KOMET-007 – AML
  • KOMET-008 – AML
  • Tipifarnib Clinical Trials
  • KURRENT-HN – HNSCC
  • KO-2806 Clinical Trials
  • FIT-001 – Solid Tumors
  • Patients & Caregivers
  • Acute Leukemias
  • Head & Neck Cancer
  • Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financial Information
  • Analyst Coverage
  • FAQs
  • Contact
  • Careers
  • Values
  • Life at Kura
  • Benefits
  • Open Positions
  • News & Media
  • Press Releases
  • News & Perspectives
  • Expert Perspectives
  • Media Resources
  • Contact

Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

Kura Oncology, Inc.
5510 Morehouse Drive, Suite 110
San Diego, California 92121

© 2025 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy

Scroll to top Scroll to top Scroll to top